Education
About Us
Working with TipRanks
Follow Us
Surrozen (SRZN)
NASDAQ:SRZN
SRZN Stock Chart & Stats
$28.54
$0.24(1.85%)
At close: 4:00 PM EST
$28.54
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$5.90 - $29.60
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$244.63M
Enterprise Value$170.38M
Total Cash (Recent Filing)$81.33M
Total Debt (Recent Filing)$7.08M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Mar 19, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.36
Shares Outstanding8,571,421
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)-1.97
Price to Sales (P/S)3.95
P/FCF Ratio-2.38
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue47.27
Enterprise Value/Gross Profit47.27
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$40.00Price Target Upside40.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Wnt-signaling PlatformSurrozen’s platform targets Wnt signaling to promote tissue repair, a specialized biological approach with high scientific barriers and broad applicability. A durable platform focus supports multi-indication R&D, potential licensing partnerships, and long-term value creation independent of short-term market moves.
Advancing Lead Candidates Toward INDA planned IND submission for SZN-8141 and ongoing development of retinal candidates signal progression from discovery to clinical development. This structural execution reduces scientific uncertainty over time and creates clear program milestones that can materially de-risk assets and enable strategic partnerships or milestone-based financing.
Experienced CFO Hire Bolsters Funding CapabilityAdding a CFO with proven capital-raising and BD experience improves the company’s long-term ability to secure financing and execute dealmaking. Strengthened financial leadership can meaningfully reduce refinancing execution risk and improve strategic portfolio prioritization over the coming funding cycles.
Bears Say
Sharp Revenue ContractionA ~71% TTM revenue decline indicates materially reduced commercial scale and weak near-term revenue runway. Persistently shrinking top-line undermines economies of scale, leaves fixed R&D and G&A costs unsupported, and makes sustainable margin recovery and self-funding of development programs unlikely without external capital.
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow reflect structural cash burn typical of R&D-stage biotech, but they necessitate repeated external financing. Over months this increases dilution risk, constrains strategic optionality, and could force prioritization or delays across development programs if capital access tightens.
Negative Stockholders' Equity Weakens Balance SheetEroded shareholders’ equity reduces financial flexibility and can complicate future financings or partnership terms. Even with modest headline debt, negative equity signals accumulated losses and elevates risk that future funding will be dilutive or costly, impacting long-term ability to sustain development programs.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $5.90 and its highest was $29.59 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $244.63M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Mar 19, 2026 which is in 14 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Nov 07, 2025. The company reported -$8.36 earnings per share for the quarter, missing the consensus estimate of -$1.135 by -$7.225.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.29.
How many shares outstanding does Surrozen have?
Surrozen has 8,571,421 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$8.36 in its last earnings report, missing expectations of -$1.135. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.00 (40.15% Upside)
$40.00 (40.15% Upside)
Hedge Fund Trend
Decreased
By 420.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
127.85%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$40.00
▲(40.15% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―